Acorda Therapeutics (ACOR) Beats Q4 EPS Expectations; Revs Heavy

Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.45, $0.27 better than the analyst estimate of $0.18. Revenue for the quarter came in at $72.64 million versus the consensus estimate of $69.16 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
• Dillard's (DDS) Tops Q2 EPS by $1.93, Misses on Revenue
• Paysafe Limited (PSFE) Misses Q2 EPS by 43c; offers guidance